Archive for the ‘biologics’ Category
Imagine knowing after 4 weeks, how a new psoriasis treatment would be working for you after 6 months…
Here’s an interesting, after-the-fact analysis from clinical trials of the biologic Ilumya (tildrakizumab-asmn), an “IL-23 inhibitor” marketed by Sun Pharma. The researchers looked at psoriasis severity scores used in clinical trials, known as PASI scores (Psoriasis Area and Severity Index), for each patient. Each patient’s score is determined before the Continue Reading…
Study finds startling rates of joint surgery in psoriatic arthritis patients
There’s a psoriatic arthritis study out of Denmark with some troubling statistics. The researchers looked at the Danish National Patient Registry from 1996 to 2017, and compared joint surgery rates between almost 12,000 psoriatic arthritis patients, and more than 100,000 people without psoriatic arthritis used as “controls” for comparison purposes. Continue Reading…
